A late-stage specialty pharmaceutical company focused on nicotine dependence, with a single lead asset, cytisinicline, being ...
PHILADELPHIA — Tavapadon, an experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson's disease (PD), was shown to significantly reduce disease burden in two ...
Activation of cannabinoid receptors in the peripheral nervous system may help treat inflammatory and gastrointestinal disorders as well as pain, and several full agonists have been reported but they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results